Changes in Osteoporosis Medication Use and Expenditures Among Women (Age More Than or Equal To 50), United States, 2000 to 2011

摘要

This Statistical Brief examines changes in osteoporosis medication use and expenditures among women (age over or equal to 50) in the United States. using nationally representative data from the 2000 to 2011 Medical Expenditure Panel Survey (MEPS). The FDA-approved medications with indication for the prevention and/or treatment of osteoporosis examined in this Statistical Brief includes anabolics (i.e., parathyroid hormone.PTH) and antiresorptives (e.g., bisphosphonates, calcitonin, and selective estrogen receptor modulators.SERMs). Data from 2000.2001 to 2010.2011 are pooled to increase sample sizes and the precision of estimates; thus, results are presented as average annual estimates for these time periods. Expenditures for all years are expressed in constant 2011 U.S. dollars. All differences between estimates discussed in the text are statistically significant at the 0.05 level unless otherwise noted. This Brief begins by presenting results on trends in the use and expenditures for medications indicated for the prevention and/or treatment of osteoporosis.